Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era.
Shindo T, Hashimoto K, Fujino K, Takahashi A, Hotta H, Maeda T, Kunishima Y, Fukuta F, Ito N, Wanifuchi A, Kato R, Okada M, Matsukawa M, Horita H, Takayanagi A, Kobayashi K, Tanaka T, Masumori N. Shindo T, et al. Among authors: takayanagi a. World J Urol. 2024 May 9;42(1):307. doi: 10.1007/s00345-024-04952-z. World J Urol. 2024. PMID: 38722418
Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
Shindo T, Hashimoto K, Takahashi A, Miyamoto S, Kunishima Y, Sato S, Fukuta F, Hiyama Y, Takayanagi A, Kato R, Wanifuchi A, Ueki Y, Okada M, Adachi H, Kobayashi KO, Tanaka T, Masumori N; Sapporo Medical University Urologic Oncology Consortium. Shindo T, et al. Among authors: takayanagi a. Anticancer Res. 2024 Mar;44(3):1271-1279. doi: 10.21873/anticanres.16922. Anticancer Res. 2024. PMID: 38423657
Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapy.
Okada M, Shindo T, Fujino K, Maeda T, Ito N, Takahashi A, Hotta H, Kunishima Y, Matsukawa M, Takayanagi A, Wanifuchi A, Nofuji S, Kato R, Fukuta F, Hashimoto K, Kobayashi K, Tanaka T, Masumori N. Okada M, et al. Among authors: takayanagi a. Support Care Cancer. 2023 Oct 3;31(10):607. doi: 10.1007/s00520-023-08087-6. Support Care Cancer. 2023. PMID: 37787829
First-in-human trial of Center Wire for neuroendovascular therapy to avoid guidewire-related complications.
Matsumoto S, Imamura H, Takayanagi A, Fukumitsu R, Goto M, Sunohara T, Fukui N, Omura Y, Akiyama T, Fukuda T, Go K, Kajiura S, Shigeyasu M, Asakura K, Horii R, Naramoto Y, Nishii R, Yamamoto Y, Sakai C, Imahori T, Kaneko N, Tateshima S, Sakai N. Matsumoto S, et al. Among authors: takayanagi a. Interv Neuroradiol. 2023 May 22:15910199231176709. doi: 10.1177/15910199231176709. Online ahead of print. Interv Neuroradiol. 2023. PMID: 37218151
First-in-human trial of Stabilizer device in neuroendovascular therapy.
Sakai C, Sakai N, Takayanagi A, Imamura H, Ohta T, Koyanagi M, Goto M, Fukumitsu R, Sunohara T, Fukui N, Matsumoto S, Akiyama T, Takano Y, Haruyama H, Go K, Kajiura S, Shigeyasu M, Asakura K, Horii R, Naramoto Y, Nishii R, Yamamoto Y, Teranishi K, Kawade S, Imahori T, Kaneko N, Tateshima S. Sakai C, et al. Among authors: takayanagi a. Heliyon. 2023 Mar 11;9(3):e14360. doi: 10.1016/j.heliyon.2023.e14360. eCollection 2023 Mar. Heliyon. 2023. PMID: 36950603 Free PMC article.
156 results